The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
Sarah J Glastras, Neale Cohen, Thomas Dover, Gary Kilov, Richard J MacIsaac, Margaret McGill, Greg R Fulcher
Journal of Clinical Medicine | MDPI | Published : 2020
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAsp), comprising rapid-acting insulin aspart and ultra-long-acting insulin degludec in solution, enables both fasting and post-prandial glucose control, with some advantages over other treatment intensification options. These include straightforward dose titration, flexibility in dose timing, low injection burden, simplicity of switching and a lower risk of hypoglycaemia. In Australia, where insulin..View full abstract
Medical writing and editorial assistance were funded by Novo Nordisk. Novo Nordisk played no role in the content of this publication.